Anti-MET Antibody Fails to Impress in Phase 3 NSCLC Trial

Onartuzumab (MetMab)did not improve PFS when combined with erlotinib (Tarceva) in the METLung trial.
Published Online: June 05, 2014

Adding the novel anti-MET monoclonal antibody onartuzumab (MetMab) to EGFR mutation-targeted therapy did not impact outcomes in a pivotal trial, although other findings suggested it may have been the population rather than the target at fault.

Progression-free survival came out nearly identical for the drug added to erlotinib (Tarceva) as with erlotinib alone (median 2.7 versus 2.6 months, P=0.92), David R. Spigel, MD, of the Sarah Cannon Research Institute in Nashville, Tenn., and colleagues found in the METLung trial.

Overall survival actually trended in favor of erlotinib alone (9.1 months versus 6.8 on the combination, P=0.07), the group reported here at the American Society of Clinical Oncology meeting.

Read the report here:
Source: Medpage Today

Recommended Articles
The deal combines Humana's 3.2 million Medicare enrollees with Aetna's 1.26 million Medicare enrollees, giving the new combined company a strong position as the baby boomer population ages.
New delivery models related to the recent healthcare reform legislation may help drive up utilization, as discussed by Francois de Brantes, MS, MBA; Ateev Mehrotra, MD, MPH; and Arthur Vercillo, MD, FACS, in this seventh segment of the Healthcare Reform Stakeholders Summit, Spring 2015 series. They theorize that healthcare convenience and availability may actually lead to a loss in coordination of care.
With a growing understanding of the risk of cardiotoxicity associated with cancer treatment, cardio-oncology has emerged as an important subspecialty, resulting in the establishment of cardio-oncology programs most often based at or in collaboration with comprehensive cancer centers.
During this one-on-one interview, a part of the Oncology Stakeholders Summit, Spring 2015 series, Michael Kolodziej, MD, discusses payer considerations regarding coverage for new cancer treatments such as immuno-oncology therapies.
Metastatic colorectal cancer patients with higher body mass index (BMI) outlived patients with the lowest BMI by an average of 2-and-a-half months, according to new data presented at the European Society for Medical Oncology 17th World Congress on Gastrointestinal Cancer 2015.